Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Haematologica ; 103(11): 1806-1814, 2018 11.
Article in English | MEDLINE | ID: mdl-29976742

ABSTRACT

A hallmark of Fanconi anemia is accelerated decline in hematopoietic stem and progenitor cells (CD34 +) leading to bone marrow failure. Long-term treatment requires hematopoietic cell transplantation from an unaffected donor but is associated with potentially severe side-effects. Gene therapy to correct the genetic defect in the patient's own CD34+ cells has been limited by low CD34+ cell numbers and viability. Here we demonstrate an altered ratio of CD34Hi to CD34Lo cells in Fanconi patients relative to healthy donors, with exclusive in vitro repopulating ability in only CD34Hi cells, underscoring a need for novel strategies to preserve limited CD34+ cells. To address this need, we developed a clinical protocol to deplete lineage+(CD3+, CD14+, CD16+ and CD19+) cells from blood and marrow products. This process depletes >90% of lineage+cells while retaining ≥60% of the initial CD34+cell fraction, reduces total nucleated cells by 1-2 logs, and maintains transduction efficiency and cell viability following gene transfer. Importantly, transduced lineage- cell products engrafted equivalently to that of purified CD34+ cells from the same donor when xenotransplanted at matched CD34+ cell doses. This novel selection strategy has been approved by the regulatory agencies in a gene therapy study for Fanconi anemia patients (NCI Clinical Trial Reporting Program Registry ID NCI-2011-00202; clinicaltrials.gov identifier: 01331018).


Subject(s)
Fanconi Anemia Complementation Group A Protein , Fanconi Anemia , Genetic Therapy , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells , Transduction, Genetic , Autografts , Child , Child, Preschool , Fanconi Anemia/genetics , Fanconi Anemia/metabolism , Fanconi Anemia/pathology , Fanconi Anemia/therapy , Fanconi Anemia Complementation Group A Protein/biosynthesis , Fanconi Anemia Complementation Group A Protein/genetics , Female , Hematopoietic Stem Cells/metabolism , Hematopoietic Stem Cells/pathology , Humans , Male , Middle Aged
2.
Indian J Med Res ; 143(2): 184-96, 2016 Feb.
Article in English | MEDLINE | ID: mdl-27121516

ABSTRACT

BACKGROUND & OBJECTIVES: Fanconi anaemia (FA) is a syndrome with a predisposition to bone marrow failure, congenital anomalies and malignancies. It is characterized by cellular hypersensitivity to cross-linking agents such as mitomycin C (MMC). In the present study, a new approach was selected to investigate FANCA (Fanconi anaemia complementation group A) gene in patients clinically diagnosed with cellular hypersensitivity to DNA cross-linking agent MMC. METHODS: Chromosomal breakage analysis was performed to prove the diagnosis of Fanconi anaemia in 318 families. Of these, 70 families had a positive result. Forty families agreed to molecular genetic testing. In total, there were 27 patients with unknown complementary types. Genomic DNA was extracted and total RNA was isolated from fresh whole blood of the patients. The first-strand cDNA was synthesized and the cDNA of each patient was then tested with 21 pairs of overlapping primers. High resolution melting curve analysis was used to screen FANCA, and LinReg software version 1.7 was utilized for analysis of expression. RESULTS: In total, six sequence alterations were identified, which included two stop codons, two frames-shift mutations, one large deletion and one amino acid exchange. FANCA expression was downregulated in patients who had sequence alterations. INTERPRETATION & CONCLUSIONS: The results of the present study show that high resolution melting (HRM) curve analysis may be useful in the detection of sequence alteration. It is simpler and more cost-effective than the multiplex ligation-dependent probe amplification (MLPA) procedure.


Subject(s)
Fanconi Anemia Complementation Group A Protein/genetics , Fanconi Anemia/genetics , Mutation , Adolescent , Adult , Child , Fanconi Anemia/epidemiology , Fanconi Anemia/pathology , Fanconi Anemia Complementation Group A Protein/biosynthesis , Female , Gene Expression Regulation , Genotype , Humans , Iran/epidemiology , Male , Middle Aged , Sequence Deletion
3.
Blood ; 124(24): 3613-23, 2014 Dec 04.
Article in English | MEDLINE | ID: mdl-25261197

ABSTRACT

Fanconi anemia (FA) is an inherited chromosomal instability syndrome that is characterized by progressive bone marrow failure. One of the main causes of morbidity and mortality in FA is a bleeding tendency, resulting from low platelet counts. Platelets are the final products of megakaryocyte (MK) maturation. Here, we describe a previously unappreciated role of Fanconi anemia group A protein (Fanca) during the endomitotic process of MK differentiation. Fanca deficiency leads to the accumulation of MKs with low nuclear ploidy and to decreased platelet production. We show, for the first time, that Fanca(-/-) mice are characterized by limited number and proliferative capacity of MK progenitors. Defective megakaryopoiesis of Fanca(-/-) cells is associated with the formation of nucleoplasmic bridges and increased chromosomal instability, indicating that inaccurate endoreplication and karyokinesis occur during MK polyploidization. Sustained DNA damage forces Fanca(-/-) MKs to enter a senescence-like state. Furthermore, inhibition of the Rho-associated kinase, a regulator of cytokinesis, improves the polyploidization of Fanca(-/-) MKs but greatly increases their genomic instability and diminishes their differentiation potential, supporting the notion that accumulation of DNA damage through endomitotic cycles affects MK maturation. Our study indicates that Fanca expression during endomitosis is crucial for normal megakaryopoiesis and platelet production.


Subject(s)
Fanconi Anemia Complementation Group A Protein , Gene Expression Regulation/genetics , Megakaryocytes/metabolism , Thrombocytopenia , Thrombopoiesis/genetics , Animals , Cellular Senescence/genetics , Chromosomal Instability/genetics , Fanconi Anemia Complementation Group A Protein/biosynthesis , Fanconi Anemia Complementation Group A Protein/genetics , Megakaryocytes/pathology , Mice , Mice, Knockout , Mitosis , Thrombocytopenia/genetics , Thrombocytopenia/metabolism , Thrombocytopenia/pathology
4.
Int J Cancer ; 130(12): 2874-85, 2012 Jun 15.
Article in English | MEDLINE | ID: mdl-21815142

ABSTRACT

Human papillomavirus (HPV) infections may result in benign hyperplasia, caused by low-risk HPV types, or (pre)malignant lesions caused by high-risk HPV types. The molecular basis of this difference in malignant potential is not completely understood. Here, we performed gene profiling of different HPV infected vulvar tissues (condylomata acuminata (n = 5), usual type vulvar intraepithelial neoplasia (uVIN) (n = 9)) and control samples (n = 14) using Affymetrix Human U133A plus 2 GeneChips. Data were analyzed using OmniViz®, Partek® and Ingenuity® Software. Results were validated by real-time RT-PCR and immunostaining. Although similarities were observed between gene expression profiles of low- and high-risk HPV infected tissues (e.g., absence of estrogen receptor in condylomata and uVIN), high-risk HPV infected tissues showed more proliferation and displayed more DNA damage than tissues infected with low-risk HPV. These observations were confirmed by differential regulation of cell cycle checkpoints and by increased expression of DNA damage-biomarkers p53 and γH2AX. Furthermore, FANCA, FANCD2, BRCA1 and RAD51, key players in the DNA damage response, were significantly upregulated (p < 0.05). In addition, we compared our results with publicly available gene expression profiles of various other HPV-induced cancers (vulva, cervix and head-and-neck). This showed p16(INK4a) was the most significant marker to detect a high-risk HPV infection, but no other markers could be found. In conclusion, this study provides insight into the molecular basis of low- and high-risk HPV infections and indicates two main pathways (cell cycle and DNA damage response) that are much stronger affected by high-risk HPV as compared to low-risk HPV.


Subject(s)
Alphapapillomavirus , Cell Cycle Checkpoints , DNA Damage , DNA Repair , Papillomavirus Infections/genetics , Vulva/pathology , Vulvar Diseases/genetics , BRCA1 Protein/biosynthesis , Biomarkers, Tumor , Condylomata Acuminata/genetics , Condylomata Acuminata/metabolism , Condylomata Acuminata/pathology , Condylomata Acuminata/virology , Cyclin-Dependent Kinase Inhibitor p16/metabolism , DNA, Viral/analysis , DNA, Viral/genetics , Fanconi Anemia Complementation Group A Protein/biosynthesis , Fanconi Anemia Complementation Group D2 Protein/biosynthesis , Female , Gene Expression Profiling , Histones/biosynthesis , Humans , Papillomavirus Infections/metabolism , Papillomavirus Infections/pathology , Papillomavirus Infections/virology , Rad51 Recombinase/biosynthesis , Tumor Suppressor Protein p53/biosynthesis , Vulva/virology , Vulvar Diseases/pathology , Vulvar Diseases/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...